These findings suggest that NSCLC patients with increased expression level of CD38 have a better clinical prognosis, and the CD38+ CD8+ T cells enriched in the tumor, are likely to be one of important candidates involved in anti-tumor-immune response. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.